Qizheng Tibetan Medicine ranked 29th on the “2022 China Top 100 Chinese Materia Medica Enterprises List.”

Release time:

2023-06-28 14:18

On the evening of June 27, the “2022 Top 100 Chinese Pharmaceutical Industry List” released by MeneNet was officially unveiled. Thanks to its solid R&D and manufacturing capabilities as well as its steady market promotion efforts, Qizheng Tibetan Medicine made it onto the “2022 Top 100 Chinese Traditional Chinese Medicine Enterprises Ranking,” placing 29th—three spots higher than the previous year.

It is reported that for this selection, Minenet has assembled an expert committee to compile the Top 100 Chinese Pharmaceutical Industry Rankings. The evaluation focuses on the innovation-driven forces and professional promotion capabilities of pharmaceutical companies, and incorporates quantitative analysis based on Minenet’s exclusive data from three major terminals and six key market segments.

Qizheng Tibetan Medicine is a leading Chinese enterprise in the Tibetan medicine industry, primarily engaged in the research and development, production, and sales of Tibetan medicines—including topical pain-relief medications, oral Tibetan formulations, and traditional Chinese medicines.

The company is among the first batch of “Innovative Enterprises” designated by the state, a national-level high-tech enterprise, a key high-tech enterprise under the National Torch Program, and a national demonstration enterprise for technological innovation. It boasts a national-level enterprise technology center as well as two national-local joint engineering laboratories—one specializing in topical Tibetan medicine preparations and the other in solid Tibetan medicine formulations. The company has successively served as the implementing unit for key projects under the nation’s “11th Five-Year Plan” for Science and Technology Support, the implementing unit for major science and technology special projects under the nation’s “12th Five-Year Plan,” and the leading unit for the key special project on “Modernization Research of Traditional Chinese Medicine” under the Ministry of Science and Technology during the nation’s “13th Five-Year Plan.” In 2022, the company was listed in the “Top 50 Chinese Herbal Medicine R&D Strength Rankings 2022,” ranking 31st. In 2023, the company unveiled its new strategy for 2023-2025—“Dual-wheel Drive, Dual Wings Leading, Dual Foundations Ensuring”—solidifying the central role of R&D strategy.

Qizheng Tibetan Medicine is patient-centered and guided by the mission of “promoting health wisdom and creating value in life.” Leveraging the unique clinical value and differentiated therapeutic advantages of Tibetan medicine, the company provides patients with excellent treatment options and clinical experiences, earning high recognition from both clinicians and patients. Between 2019 and 2022, over a three-year period, the company’s products—including Xiao Tong Tie Gao, Qing Peng Ointment, and Bai Mai Ointment—were featured in 18 guidelines and expert consensuses. The company has also received numerous honors, including “Listed Brand for China’s Household Essential Medicines” and “Brand with the Highest Recommendation Rate Among Pharmacy Staff in China.”

In the future, Qizheng Tibetan Medicine will continue to uphold its core corporate values—“acting with kindness and benefiting others, pursuing righteous paths and honest professions, respecting heaven and loving people”—while focusing on high-quality innovation and high-quality development.

Reporting media: Shanghai Securities Journal – China Securities Net

Report link: https://ggjd.cnstock.com/company/scp_ggjd/tjd_bbdj/202306/5082596.htm

Qizheng Tibetan Medicine’s net profit for the first half of 2023 increased by 34.41% year-on-year.

Qizheng Tibetan Medicine Wins the “14th China Listed Companies Investor Relations New Media Award”